New Treatment Shows Longer Survival in Myeloma Patients
A phase 3 trial found that adding felzartamab to a standard regimen may improve progression-free survival in Chinese patients with relapsed multiple myeloma. Results are preliminary and require further confirmation.
This may affect patients with relapsed myeloma; evidence comes from a phase 3 trial with limited data disclosed.
Study design and population
The trial evaluated the addition of felzartamab to lenalidomide-dexamethasone in Chinese patients with relapsed or refractory multiple myeloma.
Primary outcome
Researchers measured progression-free survival as the main outcome, with results suggesting a potential benefit.
Common questions
What is the current status of this treatment?
The treatment is under investigation in a phase 3 trial, and results are preliminary.
Who participated in the study?
The study included Chinese patients with relapsed or refractory multiple myeloma.
Sources
- Felzartamab Extends PFS in Relapsed Myeloma Medscape · medscape.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
